Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER)
A Study to Assess the Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
Sponsor: University of Minnesota
Enrolling: Male and Female Patients
Study Length: 6 Months
IRB Number: AAAQ5006
U.S. Govt. ID: NCT02414490
Contact: Arreum Kim: 2123056035 /
Additional Study Information: Subjects with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) will be enrolled in the study and Intravenous Immunoglobulin (IVIg) will be given to eligible subjects on the study. CIDP is a chronic inflammatory condition that causes the immune system to attack the nerves. IVIg is one common treatment for CIDP. IVIG is a blood product that is administered by an infusion nurse. For CIDP, IVIg is usually administered every 3 to 6 weeks. The CIDP doctor will decide how often you receive IVIg. This study is being done because we do not understand how symptoms of CIDP fluctuate (for example, wearing-off of IVIg) in between these IVIg infusions. CIDP symptoms may include weakness, numbness, pain, or difficulty walking. The goal of this study is to better understand how your CIDP symptoms change in between IVIg treatments. We hope that this information will help doctors be better able to treat patients like you with CIDP.
This study is closed
Thomas Brannagan, MD
Do You Qualify?
Receiving IVIg therapy with a treatment interval between a minimum of 21 days and a maximum of 42 days? Yes No
Are you on a stable dose of IVIg for at least 3 months prior to study participation? Yes No
Any polyneuropathy of other causes, including multifocal motor neuropathy, hereditary demyelinating neuropathy, POEMS syndrome? Yes No
The presence of any type of recent arm and/or hand bone fracture? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Arreum Kim